Comparative Assessment of Oral Estrogen and Calcium Supplement Therapy in Osteoporosis Management

Osteoporosis is a global public health problem currently affecting more than 200 million peoples worldwide. Eighty percent of people who suffer osteoporosis are women. Primary objective of our study was to carry out the comparative assessment of Estrogen and calcium supplement therapy in osteoporosis management and to assess the views of physician towards these both therapies. Secondary objectives are to determine the fastest moving brands and mostly preferred therapy for osteoporosis and prevention of this disease to the maintenance of health and quality of life. Coming to the drug therapy, about 40.5% physician reveals that Bisphosphonate therapy is used to treat osteoporosis and about 31% physician preferred calcium supplement and 20.5% physician used Estrogen replacement therapy for management of osteoporosis. 7% physicians suggest calcitonine for osteoporosis management. Chemists survey shows that the fastest moving brand of calcium are Shelcal tablet (calcium and vitamin D) and Ostocalcium tablet. In case of estrogen, Premarin tablet is the fastest moving brand. Calcium reach diet, exercise and exposure to the sun light are supportive measures for osteoporosis management.